Navigation Links
MAP Pharmaceuticals to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
Date:6/4/2008

MOUNTAIN VIEW, Calif., June 4 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference on Tuesday, June 10, 2008, at 4:00 pm (PT) in Dana Point, California.

A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The Company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
2. Antipodean Pharmaceuticals Announces FDA Acceptance of IND for MitoQ(R)
3. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
4. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
5. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
6. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
7. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
8. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
9. Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
10. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
11. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... about an increase in adolescents, marijuana use following the ... relief. According to a new study at Rhode Island ... states with and without medical marijuana laws, legalizing the ... The study is published online in advance of print ... , "Any time a state considers legalizing medical marijuana, ...
(Date:4/23/2014)... published in the journal Oncotarget , explored ... appearances or their own DNA signatures within the ... to design effective, targeted treatment strategies. , Firstly ... mutation and either the KRAS or BRAF mutation. ... the EGFR gene mutation have that specific mutation ...
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... sport in the United States with 1 million participants ... Center for Injury Research and Policy at Nationwide Children,s ... occurrence and distribution patterns of basketball-related injuries treated in ... among adolescents and teens. , The study, published online ... data relating to adolescents 13-19 years of age who ...
(Date:4/22/2014)... A recently FDA-approved device has been shown to reduce ... as 50 percent. When coupled with an innovative electrode ... device facilitated the complete elimination of seizures in nearly ... decade-long clinical trials. , That,s good news for a ... U.S. living with epilepsy whose seizures can,t be controlled ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2
... ... staggeringly researched book, A Terrible Mistake: The Murder of Frank Olson and the CIA’s Secret ... with LSD and other drugs in a series of biochemical experiments. , ... (Vocus) November 11, 2009 -- Most Americans remember ...
... ... trained to perform the latest minimally invasive single as well as double hip replacement procedures. ... (Vocus) June 29, 2009 ... Center as the 135-year-old downtown hospital,s Medical Director of Joint Replacement and Reconstruction, Dr. ...
... , ... knowledge, relocation management, and design services, Ms. McKenna and the Beyond the Box team can ... “aging in place. , ... November 11, 2009 -- The Washington, DC based relocation and design firm, Beyond the ...
... LONDON, November 11 It,s official, everyone ... from,British Lion Eggs stated that 6 out of 10 women will ... in order to look their very,shimmering best! , ... last pounds, and,still ensure you,re on tip top form. Here,s the ...
... , CHARLOTTE, N.C., Nov. 10 Anthony Asher, MD, ... NC, has co-authored the first evidence-based, multidisciplinary treatment guidelines ... at the Congress of Neurological Surgeons 2009 Annual Meeting ... year by a 20-member panel from various medical specialties. ...
... ... -- "What I,ve Learned About the Throwing Arm in the Last 30 Years" , ... Gulf Breeze, Fla. (Vocus) November 10, ... Institute will hold its inaugural Grand Rounds presentation on November, 19, 2009 at 5:30 ...
Cached Medicine News:Health News:Explosive New Book Exposes the CIA, LSD Experiments and Murder 2Health News:Explosive New Book Exposes the CIA, LSD Experiments and Murder 3Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 2Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 3Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 2Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 3Health News:realbuzz.com Top Tips to Cut the Calories This Christmas Party Season 2Health News:Local Neurosurgeon Co-Authors National Treatment Guidelines for Brain Tumor Patients 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 3
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Easy-On Knee Brace features an adjustable ... 0to 135 in 10 increments. Adjust ... to expose the stop pins and ... thick, self-padded washable fabric with Velcro ...
... BODI™ Dynamic Orthosis is the dynamic ... application over time is proven effective in ... half the time of other therapies. Can ... Orthosis.,Indications: For all joint stiffness and soft ...
... Band uses an aircell to ... tendon helping to relieve symptoms ... tendonitis. Focusing the pressure decreases ... with less constriction of the ...
... Provides shoulder ... range of motion ... rotator cuff tears, ... The shoulder brace ...
Medicine Products: